Ebola — Guinea
On [29 May 2020], the European Medicines Agency (EMA) human medicines committee recommended granting Zabdeno and Mvabea a positive opinion for marketing authorizations under exceptional circumstances because the applicant was able to demonstrate that it is not possible to conduct a randomized controlled study that might generate comprehensive clinical data on the efficacy of the latest Ebola vaccine even after authorization.
This was considered acceptable in light of the ongoing Ebola
…
